Similar Items: Development Of Recombinant Immunotherapeutics for Triple-Negative Breast Cancer (TNBC)
- Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
- Next-Generation version of pseudomonas exotoxin a based immunotoxins with reduced immunogenicity for triple negative breast cancer (TNBC) treatment
- Validation of an aASPH-SNAP-tag fusion protein for immunodiagnosis of triple-negative breast cancer
- Protein Kinase C‐Delta (PKCδ) inhibition stabilizes endothelium and suppresses triple‐negative breast cancer (TNBC) intravasation in a microfluidic hypoxic tumor model
- Generation and therapeutic evaluation of recombinant immunotherapeutics on CD64+ monocytic cell lines and polarized ex vivo differentiated human macrophages
- Lipid profile and atherogenic indices in triple-negative breast cancer
Author: Barth, Stefan
- Evaluation of tumour-associated antigens to optically label cutaneous basal cell carcinoma for surgical excision
- Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
- Generation of Glioblastoma specific SNAP based antibody fusion proteins for future radiolabelling application
- Development and Characterization of recombinant immunotoxins for cervical carcinoma
- Development of potential immunodiagnostic & therapeutic techniques using SNAP-fusion proteins as tools for the validation of Triple-negative Breast Cancer
- Comparison of the therapeutic efficacy of SNAP-tag fusion protein and the synergistic actions of chemotherapy and photodynamic therapy in killing resistant melanoma